- Our LinkedIn Page
- Our Twitter Feed
- Our Facebook Page
- Newsletter Subscribe to our monthly e-newsletter. Current Issue
- Our Flickr Feed
- Our YouTube Feed
Authors
- Abigail Hirsch
- Alan Eisenberg
- BIOtechNOW Editor
- Bruce Dale
- Celia Economides
- Colleen Lerro
- David Thomas
- George Goodno
- George MacDougall
- Jason Corum
- Jeff Joseph
- Jim Greenwood
- Karen Batra
- Kelly Cappio
- Lila Feisee
- Matt Carr
- Nathan Schock
- Paul Winters
- Paulina Ibarra
- Robbi Lycett
- Roy Zwahlen
- Sarah Sneeringer
- Sondra Behan
- Stephanie Fischer
- Stephen Marmaras
- Timothy Coetzee
- Tracy Cooley
Tags
One-on-One's Benefits of biotech crops Greenhouse Gas Emission Food Animal biotechnology global food crisis agriculture ethanol Partnering Climate Change indirect land use change BIO Investor Forum Food and Fuel Plant biotechnology BIO biotechnology Biofuel Technology renewable fuel standard greenhouse gas emissions
Tag Archives: biopharma companies
Fireside Chat with Moncef Slaoui, GlaxoSmithKline
Moncel Slaoui, chairman of research and development (R&D) at GlaxoSmithKline (GSK), opened the 2012 BIO CEO & Investor Conference with a Fireside Chat where he provided insight in to his company’s biopharma R&D strategy. “GSK has announced that our R&D budget is no more a percentage of sales. If you think about it, it doesn’t make sense,” Slaoui stated, “because, sales are a marker of R&D 10 and 15 years ago.” Right now, GSK has Read More >
Managing in a Cost-Constrained Environment
By Jill E. Sackman, D.V.M., Ph.D., Senior Consultant, and Matt Levy, J.D., Business Analyst, at Numerof & Associates, Inc. (NAI) The pharmaceutical industry has entered a critical period of transition. Business models that have proven remarkably successful over the past 20 years are now encountering major challenges. As biotech companies grapple with the leading symptoms of these challenges – pricing pressures, pipeline productivity concerns, a growing public distrust, and greater political and regulatory scrutiny – Read More >
Biopharma Industry Enthusiastic About 2012
By Eric S. Langer, president and managing partner, BioPlan Associates, Inc. 2012 Annual Study shows budgets, optimism taking a big jump It looks like the biopharma industry is actually weathering the economic downturn quite comfortably. This year we’ve surveyed hundreds of biomanufacturers and suppliers, and the industry is expressing more raw optimism and confidence than at any time in the past 9 years we’ve been surveying this industry. More Spending What this means is that wallets Read More >
2011 BIO International event spotlights expert feedback on regulatory strategy
Our good friend John Carroll, blogs on the free ranging discussion he will be hosting during the 2011 BIO International Convention, and tackling one of the most complex issues of the day for biopharma companies. You can send your questions to the panel of experts discussing the issues. In the meantime, you can also email John if there are any regulatory issues you are interested on discussing.
